Vicarious Surgical Inc. 2025 Annual Report: Key Insights and Shareholder Alerts

Overview

Vicarious Surgical Inc. (RBOT), a developer of surgical robots, has released its Annual Report for the fiscal year ended December 31, 2025. The report outlines the company’s significant operational, financial, and regulatory developments, which are crucial for current and prospective investors to consider.

Key Points from the Report

• NYSE Delisting and Trading on OTC Markets: The New York Stock Exchange (NYSE) suspended trading of Vicarious Surgical’s Class A common stock on March 3, 2026, due to the company falling below the NYSE’s minimum global market capitalization requirement of \$15 million over a 30-day period. Subsequently, the company’s shares are now quoted on the OTCID market operated by The OTC Markets Group, Inc. under the symbol “RBOT.” This transition is a significant event that may impact share liquidity, investor confidence, and the company’s ability to raise capital.
• Going Concern Warning: Management has explicitly raised substantial doubt about the company’s ability to continue as a going concern. As of December 31, 2025, Vicarious Surgical reported an accumulated deficit of \$246.1 million, with only \$2.6 million in cash and cash equivalents and \$7.2 million in short-term investments. With a recent reduction in headcount and ongoing cash burn, management expects current resources to fund operations only through the second quarter of 2026. Unless new financing is secured, the company may be forced to curtail development, reduce operations, or even liquidate its business.
• Need for Additional Funding: The company is actively seeking additional funding through public offerings, private placements, licensing and collaboration arrangements, or government funding. However, there is no assurance that such funding will be available on acceptable terms, or at all. Any new equity or debt financing could be highly dilutive to existing shareholders or impose restrictive covenants.
• Material Weakness in Internal Controls: A material weakness in internal financial reporting controls has been identified. If not remediated, this could affect the timely and accurate reporting of financial results, potentially harming investor confidence and the value of the company’s shares.
• No Revenue, Significant Losses, and Development Stage: Vicarious Surgical remains a pre-revenue, development-stage company. It has not generated revenues from product sales and continues to incur significant losses. The company anticipates further losses as it works toward regulatory approvals and commercial launch.
• Reverse Stock Split: The company executed a 1-for-30 reverse stock split, affecting all references to shares, share prices, and other per-share information on a retroactive basis. The split did not change the number of authorized shares.
• Regulatory Environment and Risks: The company’s business is subject to extensive regulation, including FDA and international requirements. Delays, non-compliance, or failure to secure necessary approvals could materially impact its ability to commercialize products.
• Business and Operational Risks: Vicarious Surgical highlights risks including reliance on sole or limited suppliers for key components, lack of experience in sales and marketing, and the need to establish and maintain adequate sales channels. The company also faces intense competition from larger, established medical device manufacturers.
• Intellectual Property Risks: The company’s ability to maintain a technological edge depends on protecting its intellectual property portfolio. Failure to do so could erode its competitive position.
• Leadership and Key Personnel: The company is highly dependent on the continued contributions of its management and key technical staff. Loss of key personnel could hinder its ability to execute its business plan.
• Legal Proceedings: As of the report date, Vicarious Surgical is not party to any material legal proceedings, though it acknowledges the risk of future litigation as part of normal business operations.
• Shareholder Information and Access: The company maintains an investor relations website and regularly posts updates, press releases, and SEC filings there.

Price-Sensitive and Potential Share Price Moving Information

• NYSE Delisting and OTC Transition: The transition from NYSE to OTC markets is a critical, price-sensitive event. It is likely to reduce share liquidity, limit access to capital markets, and result in a loss of investor confidence. The company warns that the market price may decline further, and stockholders may lose some or all of their investment.
• Going Concern and Funding Risks: The explicit warning that the company may not be able to operate beyond Q2 2026 without new funding is highly material. Failure to secure financing could result in drastic operational reductions or liquidation.
• Material Weakness in Internal Controls: The presence of a material weakness in financial controls could affect the company’s ability to accurately report its financial position, potentially leading to regulatory scrutiny, loss of investor trust, and further downward pressure on the share price.

Detailed Discussion

Liquidity and Capital Resources

As of year-end 2025, Vicarious Surgical’s cash resources are expected to last only until Q2 2026. The company is exploring multiple funding avenues, but there can be no assurance of success. If new capital is not secured, drastic cost-cutting or business liquidation may be necessary.

Delisting from NYSE

The NYSE suspended trading in RBOT shares after the company failed to meet the minimum global market capitalization requirement. The company did not appeal the delisting. Trading has shifted to the less-liquid OTCID market. This shift could:

• Reduce liquidity and share price due to the loss of NYSE market efficiencies and federal preemption of state securities laws.
• Reduce the number of investors willing to hold or acquire shares, impairing the company’s ability to raise capital.
• Prevent the company from using a registration statement to offer and sell freely tradable securities, limiting access to public capital markets.
• Impede its ability to offer equity incentives to employees and potentially result in a loss of confidence among investors, suppliers, partners, and employees.
• Result in limited news and analyst coverage, further obscuring the company’s prospects.

Operational and Strategic Risks

Vicarious Surgical is a pre-commercial, development-stage company with no product revenue to date and a consistent record of losses. It faces significant hurdles in scaling up manufacturing, establishing sales and distribution networks, and protecting its intellectual property rights. The company must also comply with a range of regulatory requirements and faces competition from established medical device manufacturers with greater resources.

Internal Controls and Reporting

The company has identified a material weakness in its internal control over financial reporting. If not remediated, this may cause delays or errors in financial disclosures, which could further erode investor confidence.

Conclusion

The 2025 Annual Report from Vicarious Surgical Inc. contains several critical disclosures with direct implications for shareholder value. The NYSE delisting, ongoing liquidity crisis, and material weakness in internal controls represent major risks. Investors should closely monitor the company’s funding efforts and regulatory status, as failure to address these issues could result in further share price declines or even business failure.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should carefully review the company’s full SEC filings and consult their own financial advisors before making investment decisions. The information summarized here is based on the company’s official filings as of March 9, 2026, and may not reflect subsequent developments.

View Vicarious Surgical Inc. Historical chart here